Optimizing the Quality of the Colorectal Cancer Screening Continuum: A Call to Action

Journal of the National Cancer Institute

Volumn 109, Issue 5, 2017, Pages

  Gupta, Samir ^a,b,c   Nodora, Jesse ^b,d  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC; HEMOGLOBIN;

ADVERSE OUTCOME; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL POLYP; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST; EARLY CANCER DIAGNOSIS; EDITORIAL; FECAL IMMUNOCHEMISTRY; FOLLOW UP; GROUPS BY AGE; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD; PRIORITY JOURNAL; QUALITY CONTROL; SIGMOIDOSCOPY; COLORECTAL TUMOR; STANDARDS;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 85021318575     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw271     Document Type: Editorial

References (17)

1. American Cancer Society. Global Cancer Facts & Figures. 3rd ed. Atlanta, GA: American Cancer Society; 2015.
2. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564-2575.
3. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies. Arch Intern Med. 2012; 172(7):575-582.
4. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: A randomized clinical trial. JAMA Intern Med. 2013;173(18):1725-1732.
5. Singal AG, Gupta S, Tiro JA, et al. Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system. Cancer. 2016;122(3):456-463.
6. Tiro JA, Kamineni A, Levin TR, et al. The colorectal cancer screening process in community settings: A conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1147-1158.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
8. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: A retrospective cohort study. Ann Intern Med. 2016;164(7):456-463.
9. Jimbo M, Myers RE, Meyer B, et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med. 2009;7(1):11-16.
10. Humphrey LL, Shannon J, Partin MR, et al. Improving the follow-up of positive hemoccult screening tests: An electronic intervention. J Gen Intern Med. 2011;26(7):691-697.
11. Rao SK, Schilling TF, Sequist TD. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med. 2009;24(3):356-360.
12. Chubak J, Garcia MP, Burnett-Hartman AN, et al. Time to colonoscopy after positive fecal blood test in four U.S. health care systems. Cancer Epidemiol Biomarkers Prev. 2016;25(2):344-350.
13. Meester RG, Zauber AG, Doubeni CA, et al. Consequences of increasing time to colonoscopy examination after positive result from fecal colorectal cancer screening test. Clin Gastroenterol Hepatol. 2016;14(10): 1445-1451.
14. Lee Y, Chen SL, Yen AM, et al. Colorectal cancer mortality of colonoscopy noncompliers with gradient fecal hemoglobin concentration. J Natl Cancer Inst. 2016;109(5):djw269 doi: 10.1093/jnci/djw269.
15. Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf. 2008;34(4):228-243.
16. von Karsa L, Patnick J, Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition-executive summary. Endoscopy. 2012;44(S 03):SE1-SE8.
17. Robertson DJ, Lee JK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, Lieberman D, Levin TR, Rex DK. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Oct 18. pii: S0016-5085(16)35025-9. doi: 10.1053/j.gastro. 2016.08.053. PubMed PMID: 27769517